Clinical Trials Logo

Shock clinical trials

View clinical trials related to Shock.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05001854 Suspended - Septic Shock Clinical Trials

Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients

FLUDROSEPSIS
Start date: March 31, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The benefit of low-dose steroids in septic shock is still debated today, especially with mineralocorticoids. Fludrocortisone is a synthetic mineralocorticoid, an analogue of aldosterone, which has shown, in combination with hydrocortisone, a favorable effect on the mortality of septic shock patients with relative adrenal insufficiency. In a previous study in healthy volunteers, we showed for the first time that fludrocortisone at a dose of 400 μg per day significantly improved the pressor response to phenylephrine. These results confirm the observations reported in rats with endotoxin shock, where fludrocortisone was shown to significantly increase blood pressure and contractile response to phenylephrine. These encouraging results argue for a potential vascular beneficial effect of fludrocortisone and need to be confirmed in a population of septic shock patients. In this context, we aimed to evaluate the effect of oral administration of 100 μg every 6 hours of fludrocortisone on vascular responsiveness to noradrenaline in septic shock patients.

NCT ID: NCT04742764 Suspended - Septic Shock Clinical Trials

Extracorporal Cytokin Removal in Septic Shock: a Prospective, Randomized, Multicenter Clinical Trial

DECRISS
Start date: January 1, 2024
Phase: Phase 3
Study type: Interventional

Sepsis and septic shock have mortality rates between 20-50%. When standard therapeutic measures fail to improve patients' condition, additional therapeutic alternatives are applied to reduce morbidity and mortality. One of the most recent alternatives is extracorporeal cytokine hemoadsorption. One of the most tested devices is CytoSorb, however, there are a lot of open questions, such timing, dosing and of course its overall efficacy. This study aims to compare the efficacy of standard medical therapy (Group A, SMT) and continuous extracorporeal cytokine removal with CytoSorb therapy in patients with early refractory septic shock. Furthermore, we compare the dosing of CytoSorb adsorber device - as the cartridge will be changed in every (12 Group B) or 24 hours (Group C).

NCT ID: NCT04184635 Suspended - Clinical trials for Acute Myocardial Infarction

Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock

ANCHOR
Start date: October 14, 2021
Phase: N/A
Study type: Interventional

Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days). An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.

NCT ID: NCT03302650 Suspended - Septic Shock Clinical Trials

Angiotensin II for Septic Shock Treatment

Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

This study aims to investigate the effect of angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.

NCT ID: NCT03193164 Suspended - Shock, Septic Clinical Trials

Neuromuscular Electrical Stimulation and Septic Shock

Start date: November 13, 2018
Phase: N/A
Study type: Interventional

The study will investigate the effects of neuromuscular electrical stimulation (NMES) in patients with septic shock. The objective of this study will be investigate the effects of neuromuscular electrical stimulation (NMES) in patients with septic shock.